Related references
Note: Only part of the references are listed.Chemotherapy Before Liver Resection of Colorectal Metastases Friend or Foe?
Kuno Lehmann et al.
ANNALS OF SURGERY (2012)
Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases
Hannes P. Neeff et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2012)
Reversibility of capillary density after discontinuation of bevacizumab treatment
N. Steeghs et al.
ANNALS OF ONCOLOGY (2010)
Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab A Case-Controlled Study
Dietmar Tamandl et al.
ANNALS OF SURGERY (2010)
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis
Laura Rubbia-Brandt et al.
HISTOPATHOLOGY (2010)
Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study
Mahfud Mahfud et al.
WORLD JOURNAL OF SURGERY (2010)
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
M. Klinger et al.
EJSO (2009)
Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
Yun Shin Chun et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality?
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases
Susan B. Kesmodel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Dan G. Blazer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
Brigit Gruenberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
Srinevas K. Reddy et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Targeted therapies and surgical issues in gastrointestinal cancers
Alexander A. Parikh et al.
TARGETED ONCOLOGY (2008)
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
Dario Ribero et al.
CANCER (2007)
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery
L. Rubbia-Brandt et al.
ANNALS OF ONCOLOGY (2007)
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study
Michael D'Angelica et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
FA Scappaticci et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT)
SG Swisher et al.
ANNALS OF SURGERY (2005)
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome
JA Ajani et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
MS Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
